Application of Immune Checkpoint Inhibitors in Cancer

Abstract

Cancer is a significant challenge to society and public health in the 21st century. According to GLOBOCAN 2020, there were 19.3 million new cancer cases with approximately 10.0 million deaths in 2020 globally. By 2040, 28 million new cases and 16.2 million deaths are estimated. With the escalating challenges of cancer and limitations of conventional therapies like surgery, chemotherapy, and radiotherapy, the development of novel therapies such as immunotherapy and targeted therapy is required. Immunotherapy, especially immune checkpoint inhibitors (ICIs), has become a significant advancement in cancer treatment, combating tumors by activating the immune system. This review offers a thorough overview of ICIs, including their classification, mechanisms of action, and adverse events. It also examines the application of ICIs across various cancer types especially on advanced or unresectable malignancies, such as head and neck squamous cell carcinoma, esophageal cancer, non-small cell lung cancer, breast cancer, hepatocellular carcinoma, and bladder cancer, highlighting their therapeutic potential and the challenges they face. By providing a comprehensive analysis, this review aims to construct a reference system for clinicians to better understand and utilize ICIs in treating cancer.

Keywords

Adverse events / Advanced malignancies / Clinical application / Immune checkpoints / Immune checkpoint inhibitors

References

[1] F. Bray, M. Laversanne, H. Sung, et al., “Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 74, no. 3 (2024): 229-263.

[2] B. Liu, H. Zhou, L. Tan, K. T. H. Siu, and X. Y. Guan, “Exploring Treatment Options in Cancer: Tumor Treatment Strategies,” Signal Transduction and Targeted Therapy 9, no. 1 (2024): 175.

[3] R. Kaur, A. Bhardwaj, and S. Gupta, “Cancer Treatment Therapies: Traditional to Modern Approaches to Combat Cancers,” Molecular Biology Reports 50, no. 11 (2023): 9663-9676.

[4] J. F. Brunet, F. Denizot, M. F. Luciani, et al., “A New Member of the Immunoglobulin Superfamily-CTLA-4,” Nature 328, no. 6127 (1987): 267-270.

[5] D. R. Leach, M. F. Krummel, and J. P. Allison, “Enhancement of Antitumor Immunity by CTLA-4 Blockade,” Science (New York, NY) 271, no. 5256 (1996): 1734-1736.

[6] Y. Ishida, Y. Agata, K. Shibahara, and T. Honjo, “Induced Expression of PD-1, a Novel Member of the Immunoglobulin Gene Superfamily, Upon Programmed Cell Death,” Embo Journal 11, no. 11 (1992): 3887-3895.

[7] H. Dong, G. Zhu, K. Tamada, and L. Chen, “B7-H1, a Third Member of the B7 family, co-stimulates T-cell Proliferation and Interleukin-10 Secretion,” Nature Medicine 5, no. 12 (1999): 1365-1369.

[8] H. Dong, S. E. Strome, D. R. Salomao, et al., “Tumor-associated B7-H1 Promotes T-cell Apoptosis: A Potential Mechanism of Immune Evasion,” Nature Medicine 8, no. 8 (2002): 793-800.

[9] F. Cameron, G. Whiteside, and C. Perry, “Ipilimumab: First Global Approval,” Drugs 71, no. 8 (2011): 1093-1104.

[10] M. Hazarika, M. K. Chuk, M. R. Theoret, et al., “FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab,” Clinical Cancer Research: an Official Journal of the American Association for Cancer Research 23, no. 14 (2017): 3484-3488.

[11] Y. M. Ning, D. Suzman, V. E. Maher, et al., “FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy,” The Oncologist 22, no. 6 (2017): 743-749.

[12] Y. Wang, H. Zhang, C. Liu, et al., “Immune Checkpoint Modulators in Cancer Immunotherapy: Recent Advances and Emerging Concepts,” Journal of Hematology & Oncology 15, no. 1 (2022): 111.

[13] W. H. Fridman, L. Zitvogel, C. Sautès-Fridman, and G. Kroemer, “The Immune Contexture in Cancer Prognosis and Treatment,” Nature Reviews Clinical Oncology 14, no. 12 (2017): 717-734.

[14] B. Wu, B. Zhang, B. Li, H. Wu, and M. Jiang, “Cold and Hot Tumors: From Molecular Mechanisms to Targeted Therapy,” Signal Transduction and Targeted Therapy 9, no. 1 (2024): 274.

[15] L. Marcus, S. J. Lemery, P. Keegan, and R. Pazdur, “FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors,” Clinical Cancer Research: an Official Journal of the American Association for Cancer Research 25, no. 13 (2019): 3753-3758.

[16] Y. Wang, Z. Tong, W. Zhang, et al., “FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients,” Frontiers in Oncology 11 (2021): 683419.

[17] L. Wang, H. Geng, Y. Liu, et al., “Hot and Cold Tumors: Immunological Features and the Therapeutic Strategies,” MedComm 4, no. 5 (2023): e343.

[18] K. Esfahani, L. Roudaia, N. Buhlaiga, S. V. Del Rincon, N. Papneja, and W. H. Miller, “A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future,” Current Oncology 27, no. S2 (2020): S87-s97.

[19] M. Arafat Hossain, “A Comprehensive Review of Immune Checkpoint Inhibitors for Cancer Treatment,” International Immunopharmacology 143, no. Pt 2 (2024): 113365.

[20] A. Schnell, L. Bod, A. Madi, and V. K. Kuchroo, “The Yin and Yang of co-inhibitory Receptors: Toward Anti-tumor Immunity without Autoimmunity,” Cell Research 30, no. 4 (2020): 285-299.

[21] A. C. Anderson, N. Joller, and V. K. Kuchroo, “Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation,” Immunity 44, no. 5 (2016): 989-1004.

[22] B. Thapa, S. Kato, D. Nishizaki, et al., “OX40/OX40 ligand and Its Role in Precision Immune Oncology,” Cancer and Metastasis Reviews 43, no. 3 (2024): 1001-1013.

[23] H. E. Marei, A. Hasan, G. Pozzoli, and C. Cenciarelli, “Cancer Immunotherapy with Immune Checkpoint Inhibitors (ICIs): Potential, Mechanisms of Resistance, and Strategies for Reinvigorating T Cell Responsiveness When Resistance Is Acquired,” Cancer Cell International 23, no. 1 (2023): 64.

[24] A. J. Korman, S. C. Garrett-Thomson, and N. Lonberg, “The Foundations of Immune Checkpoint Blockade and the Ipilimumab Approval Decennial,” Nature Reviews Drug Discovery 21, no. 7 (2022): 509-528.

[25] S. J. Keam, “Tremelimumab: First Approval,” Drugs 83, no. 1 (2023): 93-102.

[26] B. Tang, Y. Chen, Y. Jiang, et al., “Toripalimab in Combination with HBM4003, an Anti-CTLA-4 Heavy Chain-only Antibody, in Advanced Melanoma and Other Solid Tumors: An Open-label Phase I Trial,” Journal for Immunotherapy of Cancer 12, no. 10 (2024).

[27] A. Tarhini, “Immune-Mediated Adverse Events Associated With Ipilimumab Ctla-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management,” Scientifica (Cairo) 2013 (2013): 857519.

[28] S. H. Jaber, E. W. Cowen, L. R. Haworth, et al., “Skin Reactions in a Subset of Patients with Stage IV Melanoma Treated with Anti-cytotoxic T-lymphocyte Antigen 4 Monoclonal Antibody as a Single Agent,” Archives of Dermatology 142, no. 2 (2006): 166-172.

[29] P. Attia, G. Q. Phan, A. V. Maker, et al., “Autoimmunity Correlates with Tumor Regression in Patients with Metastatic Melanoma Treated with Anti-cytotoxic T-lymphocyte Antigen-4,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 23, no. 25 (2005): 6043-6053.

[30] A. A. Tarhini, N. Kang, S. J. Lee, et al., “Immune Adverse Events (irAEs) with Adjuvant Ipilimumab in Melanoma, Use of Immunosuppressants and Association With Outcome: ECOG-ACRIN E1609 Study Analysis,” Journal for Immunotherapy of Cancer 9, no. 5 (2021).

[31] B. Shulgin, Y. Kosinsky, A. Omelchenko, et al., “Dose Dependence of Treatment-related Adverse Events for Immune Checkpoint Inhibitor Therapies: A Model-based Meta-analysis,” Oncoimmunology 9, no. 1 (2020): 1748982.

[32] Y. Yoshikawa, M. Imamura, M. Yamauchi, et al., “Prevalence of Immune-related Adverse Events and Anti-tumor Efficacy Following Immune Checkpoint Inhibitor Therapy in Japanese Patients with Various Solid Tumors,” BMC Cancer 22, no. 1 (2022): 1232.

[33] N. Patsoukis, Q. Wang, L. Strauss, and V. A. Boussiotis, “Revisiting the PD-1 Pathway,” Science Advances 6, no. 38 (2020).

[34] Y. Iwai, M. Ishida, Y. Tanaka, T. Okazaki, T. Honjo, and N. Minato, “Involvement of PD-L1 on Tumor Cells in the Escape from Host Immune System and Tumor Immunotherapy by PD-L1 Blockade,” Proceedings of the National Academy of Sciences of the United States of America 99, no. 19 (2002): 12293-12297.

[35] Y. Godiyal, D. Maheshwari, H. Taniguchi, et al., “Role of PD-1/PD-L1 Signaling Axis in Oncogenesis and Its Targeting by Bioactive Natural Compounds for Cancer Immunotherapy,” Military Medical Research 11, no. 1 (2024): 82.

[36] X. Lin, K. Kang, P. Chen, et al., “Regulatory Mechanisms of PD-1/PD-L1 in Cancers,” Molecular Cancer 23, no. 1 (2024): 108.

[37] C. O. Ladjevardi, M. Skribek, A. Koliadi, et al., “Differences in Immune-related Toxicity between PD-1 and PD-L1 Inhibitors: A Retrospective Cohort Study in Patients with Advanced Cancer,” Cancer Immunology, Immunotherapy 74, no. 1 (2024): 14.

[38] V. Ruste, V. Goldschmidt, A. Laparra, et al., “The Determinants of Very Severe Immune-related Adverse Events Associated with Immune Checkpoint Inhibitors: A Prospective Study of the French REISAMIC Registry,” European Journal of Cancer (Oxford, England: 1990) 158 (2021): 217-224.

[39] L. Khoja, D. Day, T. Wei-Wu Chen, L. L. Siu, and A. R. Hansen, “Tumour- and Class-specific Patterns of Immune-related Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review,” Annals of Oncology: Official Journal of the European Society for Medical Oncology 28, no. 10 (2017): 2377-2385.

[40] K. S. Ma, C. H. Chiang, S. T. Chen, et al., “Periodontitis Is an Immune-related Adverse Event Associated with Immune Checkpoint Inhibitors: A Multi-center Cohort Study,” Cancer Letters 598 (2024): 217100.

[41] J. Chen, J. S. Liu, J. Y. Liu, et al., “Plasma Metabolomics of Immune-related Adverse Events for Patients with Lung Cancer Treated with PD-1/PD-L1 Inhibitors,” Journal for Immunotherapy of Cancer 12, no. 7 (2024).

[42] Y. Liu, X. Liu, N. Zhang, et al., “Berberine Diminishes Cancer Cell PD-L1 Expression and Facilitates Antitumor Immunity via Inhibiting the Deubiquitination Activity of CSN5,” Acta Pharmaceutica Sinica. B 10, no. 12 (2020): 2299-2312.

[43] R. Dutta, R. Khalil, K. Mayilsamy, et al., “Combination Therapy of Mithramycin A and Immune Checkpoint Inhibitor for the Treatment of Colorectal Cancer in an Orthotopic Murine Model,” Frontiers in Immunology 12 (2021): 706133.

[44] Y. Zhang, Y. Huang, D. Yu, et al., “Demethylzeylasteral Induces PD-L1 Ubiquitin-proteasome Degradation and Promotes Antitumor Immunity via Targeting USP22,” Acta Pharmaceutica Sinica. B 14, no. 10 (2024): 4312-4328.

[45] V. Aggarwal, C. J. Workman, and D. A. A. Vignali, “LAG-3 as the Third Checkpoint Inhibitor,” Nature Immunology 24, no. 9 (2023): 1415-1422.

[46] R. J. Kelly, B. V. Landon, A. H. Zaidi, et al., “Neoadjuvant Nivolumab or Nivolumab plus LAG-3 Inhibitor Relatlimab in Resectable Esophageal/Gastroesophageal Junction Cancer: A Phase Ib Trial and ctDNA Analyses,” Nature Medicine 30, no. 4 (2024): 1023-1034.

[47] A. R. Cillo, C. Cardello, F. Shan, et al., “Blockade of LAG-3 and PD-1 Leads to co-expression of Cytotoxic and Exhaustion Gene Modules in CD8(+) T Cells to Promote Antitumor Immunity,” Cell 187, no. 16 (2024): 4373-4388.

[48] L. P. Andrews, S. C. Butler, J. Cui, et al., “LAG-3 and PD-1 Synergize on CD8(+) T Cells to Drive T Cell Exhaustion and Hinder Autocrine IFN-γ-dependent Anti-tumor Immunity,” Cell 187, no. 16 (2024): 4355-4372.

[49] L. Cai, Y. Li, J. Tan, L. Xu, and Y. Li, “Targeting LAG-3, TIM-3, and TIGIT for Cancer Immunotherapy,” Journal of Hematology & Oncology 16, no. 1 (2023): 101.

[50] S. Ma, Y. Tian, J. Peng, et al., “Identification of a Small-molecule Tim-3 Inhibitor to Potentiate T Cell-mediated Antitumor Immunotherapy in Preclinical Mouse Models,” Science Translational Medicine 15, no. 722 (2023): eadg6752.

[51] Z. Zhang, C. Ren, R. Xiao, et al., “Palmitoylation of TIM-3 Promotes Immune Exhaustion and Restrains Antitumor Immunity,” Science Immunology 9, no. 101 (2024): eadp7302.

[52] G. Curigliano, H. Gelderblom, N. Mach, et al., “Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors,” Clinical Cancer Research: an Official Journal of the 27, no. 13 (2021): 3620-3629.

[53] A. Hollebecque, H. C. Chung, M. J. de Miguel, et al., “Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors,” Clinical Cancer Research: an Official Journal of the 27, no. 23 (2021): 6393-6404.

[54] X. Guan, R. Hu, Y. Choi, et al., “Anti-TIGIT Antibody Improves PD-L1 Blockade through Myeloid and T(reg) Cells,” Nature 627, no. 8004 (2024): 646-655.

[55] D. Piovesan, A. E. de Groot, S. Cho, et al., “Fc-Silent Anti-TIGIT Antibodies Potentiate Antitumor Immunity without Depleting Regulatory T Cells,” Cancer Research 84, no. 12 (2024): 1978-1995.

[56] B. C. Cho, D. R. Abreu, M. Hussein, et al., “Tiragolumab plus Atezolizumab versus Placebo plus Atezolizumab as a First-line Treatment for PD-L1-selected Non-small-cell Lung Cancer (CITYSCAPE): Primary and Follow-up Analyses of a Randomised, Double-blind, Phase 2 Study,” The Lancet Oncology 23, no. 6 (2022): 781-792.

[57] J. Niu, C. Maurice-Dror, D. H. Lee, et al., “First-in-human Phase 1 Study of the Anti-TIGIT Antibody Vibostolimab as Monotherapy or with Pembrolizumab for Advanced Solid Tumors, Including Non-small-cell Lung Cancer(☆),” Annals of Oncology: Official Journal of the European Society for Medical Oncology 33, no. 2 (2022): 169-180.

[58] S. Frentzas, S. Kao, R. Gao, et al., “AdvanTIG-105: A Phase I Dose Escalation Study of the Anti-TIGIT Monoclonal Antibody Ociperlimab in Combination with Tislelizumab in Patients with Advanced Solid Tumors,” Journal for Immunotherapy of Cancer 11, no. 10 (2023).

[59] S. Iadonato, Y. Ovechkina, K. Lustig, et al., “A Highly Potent Anti-VISTA Antibody KVA12123 - a New Immune Checkpoint Inhibitor and a Promising Therapy against Poorly Immunogenic Tumors,” Frontiers in Immunology 14 (2023): 1311658.

[60] C. Aggarwal, A. Prawira, S. Antonia, et al., “Dual Checkpoint Targeting of B7-H3 and PD-1 with Enoblituzumab and Pembrolizumab in Advanced Solid Tumors: Interim Results From a Multicenter Phase I/II Trial,” Journal for Immunotherapy of Cancer 10, no. 4 (2022).

[61] S. B. Gitto, M. Whicker, G. Davies, et al., “A B7-H4-Targeting Antibody-Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression,” Clinical Cancer Research: an Official Journal of the 30, no. 8 (2024): 1567-1581.

[62] H. Sung, J. Ferlay, R. L. Siegel, et al., “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 71, no. 3 (2021): 209-249.

[63] L. Q. M. Chow, “Head and Neck Cancer,” The New England Journal of Medicine 382, no. 1 (2020): 60-72.

[64] D. E. Johnson, B. Burtness, C. R. Leemans, V. W. Y. Lui, J. E. Bauman, and J. R. Grandis, “Head and Neck Squamous Cell Carcinoma,” Nature Reviews Disease Primers 6, no. 1 (2020): 92.

[65] S. Marur and A. A. Forastiere, “Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment,” Mayo Clinic Proceedings 91, no. 3 (2016): 386-396.

[66] K. Parmar, A. Mohamed, E. Vaish, R. Thawani, J. Cetnar, and K. Z. Thein, “Immunotherapy in Head and Neck Squamous Cell Carcinoma: An Updated Review,” Cancer Treatment and Research Communications 33 (2022): 100649.

[67] P. Nenclares, A. Rullan, K. Tam, L. A. Dunn, M. St John, and K. J. Harrington, “Introducing Checkpoint Inhibitors Into the Curative Setting of Head and Neck Cancers: Lessons Learned, Future Considerations,” American Society of Clinical Oncology Educational Book 42 (2022): 1-16.

[68] T. Y. Seiwert, B. Burtness, R. Mehra, et al., “Safety and Clinical Activity of Pembrolizumab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE-012): An Open-label, Multicentre, Phase 1b Trial,” The Lancet Oncology 17, no. 7 (2016): 956-965.

[69] R. L. Ferris, G. Blumenschein, J. Fayette, et al., “Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck,” The New England Journal of Medicine 375, no. 19 (2016): 1856-1867.

[70] E. E. W. Cohen, D. Soulières, C. Le Tourneau, et al., “Pembrolizumab versus Methotrexate, Docetaxel, or Cetuximab for Recurrent or Metastatic Head-and-neck Squamous Cell Carcinoma (KEYNOTE-040): A Randomised, Open-label, Phase 3 Study,” Lancet (London, England) 393, no. 10167 (2019): 156-167.

[71] K. J. Harrington and R. L. Ferris, “Nivolumab versus Standard, Single-agent Therapy of Investigator's Choice in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (CheckMate 141): Health-related Quality-of-life Results from a Randomised, Phase 3 Trial,” The Lancet Oncology 18, no. 8 (2017): 1104-1115.

[72] R. Uppaluri, K. M. Campbell, A. M. Egloff, et al., “Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial,” Clinical Cancer Research: an Official Journal of the 26, no. 19 (2020): 5140-5152.

[73] T. M. Wise-Draper, S. Gulati, S. Palackdharry, et al., “Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma,” Clinical Cancer Research: an Official Journal of the 28, no. 7 (2022): 1345-1352.

[74] R. Uppaluri, N. Y. Lee, W. Westra, et al., KEYNOTE-689: Phase 3 Study of Adjuvant and Neoadjuvant Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma. (American Society of Clinical Oncology, 2019).

[75] B. Burtness, K. J. Harrington, R. Greil, et al., “Pembrolizumab Alone or with Chemotherapy versus Cetuximab with Chemotherapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE-048): A Randomised, Open-label, Phase 3 Study,” Lancet (London, England) 394, no. 10212 (2019): 1915-1928.

[76] M. Tahara, R. Greil, D. Rischin, et al., “659MO Pembrolizumab with or without Chemotherapy for First-line Treatment of Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): 5-year Results from KEYNOTE-048,” Annals of Oncology 33 (2022): S844.

[77] R. Zinner, J. M. Johnson, M. Tuluc, et al., Neoadjuvant Nivolumab (N) plus Weekly Carboplatin (C) and Paclitaxel (P) in Resectable Locally Advanced Head and Neck Cancer. (American Society of Clinical Oncology, 2020).

[78] X. Huang, Q. Liu, G. Zhong, et al., “Neoadjuvant Toripalimab Combined with Gemcitabine and Cisplatin in Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (NeoTGP01): An Open Label, Single-arm, Phase Ib Clinical Trial,” Journal of Experimental & Clinical Cancer Research 41, no. 1 (2022): 300.

[79] Z. Zhang, B. Wu, G. Peng, et al., “Neoadjuvant Chemoimmunotherapy for the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: A Single-Arm Phase 2 Clinical Trial,” Clinical Cancer Research: an Official Journal of the American Association for Cancer Research 28, no. 15 (2022): 3268-3276.

[80] J. D. Schoenfeld, G. J. Hanna, V. Y. Jo, et al., “Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial,” JAMA Oncology 6, no. 10 (2020): 1563-1570.

[81] J. L. Vos, J. B. W. Elbers, O. Krijgsman, et al., “Neoadjuvant Immunotherapy With Nivolumab and Ipilimumab Induces Major Pathological Responses in Patients With Head and Neck Squamous Cell Carcinoma,” Nature Communications 12, no. 1 (2021): 7348.

[82] R. Leidner, M. Crittenden, K. Young, et al., “Neoadjuvant Immunoradiotherapy Results in High Rate of Complete Pathological Response and Clinical to Pathological Downstaging in Locally Advanced Head and Neck Squamous Cell Carcinoma,” Journal for Immunotherapy of Cancer 9, no. 5 (2021).

[83] P. Shen, B. Qiao, N. Jin, and S. Wang, “Neoadjuvant Immunoradiotherapy in Patients with Locally Advanced Oral Cavity Squamous Cell Carcinoma: A Retrospective Study,” Investigational New Drugs 40, no. 6 (2022): 1282-1289.

[84] A. G. Sacco, R. Chen, F. P. Worden, et al., “Pembrolizumab plus Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: An Open-label, Multi-arm, Non-randomised, Multicentre, Phase 2 Trial,” The Lancet Oncology 22, no. 6 (2021): 883-892.

[85] C. H. Chung, J. Li, C. E. Steuer, et al., “Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma,” Clinical Cancer Research: an Official Journal of the 28, no. 11 (2022): 2329-2338.

[86] N. F. Saba, C. E. Steuer, A. Ekpenyong, et al., “Pembrolizumab and Cabozantinib in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 2 Trial,” Nature Medicine 29, no. 4 (2023): 880-887.

[87] L. Licitra, M. Tahara, K. Harrington, et al., “Pembrolizumab with or without Lenvatinib as First-line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC): Phase 3 LEAP-010 Study,” International Journal of Radiation Oncology* Biology* Physics 118, no. 5 (2024): e2-e3.

[88] W. T. Ju, R. H. Xia, D. W. Zhu, et al., “A Pilot Study of Neoadjuvant Combination of Anti-PD-1 Camrelizumab and VEGFR2 Inhibitor Apatinib for Locally Advanced Resectable Oral Squamous Cell Carcinoma,” Nature Communications 13, no. 1 (2022): 5378.

[89] B. C. Cho, O. Hamid, X. Zhu, et al., A Phase 1 Study of fianlimab (anti-LAG-3) in Combination with cemiplimab (anti-PD-1) in Patients with Advanced HNSCC. (American Society of Clinical Oncology, 2024).

[90] D. Adkins, V. Cheshuk, J. A. Peguero, et al., TACTI-003: A Randomized Phase IIb Study of Eftilagimod Alpha (soluble LAG-3 protein) and Pembrolizumab as First-line Treatment of Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. (American Society of Clinical Oncology, 2022).

[91] C. M. Rudin, S. V. Liu, R. A. Soo, et al., “SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 42, no. 3 (2024): 324-335.

[92] D. Romero, “Immunotherapy: PD-1 Says Goodbye, TIM-3 Says Hello,” Nature Reviews Clinical Oncology 13, no. 4 (2016): 202-203.

[93] J. E. Kim, M. A. Patel, A. Mangraviti, et al., “Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas,” Clinical Cancer Research: an Official Journal of the 23, no. 1 (2017): 124-136.

[94] Y. Song, L. Li, Y. Ou, et al., “Identification of Genomic Alterations in Oesophageal Squamous Cell Cancer,” Nature 509, no. 7498 (2014): 91-95.

[95] T. Doi, S. A. Piha-Paul, S. I. Jalal, et al., “Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 36, no. 1 (2018): 61-67.

[96] R. J. Kelly, J. A. Ajani, J. Kuzdzal, et al., “Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer,” The New England Journal of Medicine 384, no. 13 (2021): 1191-1203.

[97] J. M. Sun, L. Shen, M. A. Shah, et al., “Pembrolizumab plus Chemotherapy versus Chemotherapy Alone for First-line Treatment of Advanced Oesophageal Cancer (KEYNOTE-590): A Randomised, Placebo-controlled, Phase 3 Study,” Lancet (London, England) 398, no. 10302 (2021): 759-771.

[98] Y. Y. Janjigian, K. Shitara, M. Moehler, et al., “First-line Nivolumab Plus Chemotherapy Versus Chemotherapy Alone for Advanced Gastric, Gastro-oesophageal Junction, and Oesophageal Adenocarcinoma (CheckMate 649): A Randomised, Open-label, Phase 3 Trial,” Lancet (London, England) 398, no. 10294 (2021): 27-40.

[99] S. Yamamoto and K. Kato, “JUPITER-06 Establishes Immune Checkpoint Inhibitors as Essential First-line Drugs for the Treatment of Advanced Esophageal Squamous Cell Carcinoma,” Cancer Cell 40, no. 3 (2022): 238-240.

[100] Z. X. Wang, C. Cui, J. Yao, et al., “Toripalimab plus Chemotherapy in Treatment-naïve, Advanced Esophageal Squamous Cell Carcinoma (JUPITER-06): A Multi-center Phase 3 Trial,” Cancer Cell 40, no. 3 (2022): 277-288. e3.

[101] Z. Lu, J. Wang, Y. Shu, et al., “Sintilimab versus Placebo in Combination with Chemotherapy as First Line Treatment for Locally Advanced or Metastatic Oesophageal Squamous Cell Carcinoma (ORIENT-15): Multicentre, Randomised, Double Blind, Phase 3 Trial,” BMJ 377 (2022): e068714.

[102] J. Xu, K. Kato, E. Raymond, et al., “Tislelizumab plus Chemotherapy versus Placebo plus Chemotherapy as First-line Treatment for Advanced or Metastatic Oesophageal Squamous Cell Carcinoma (RATIONALE-306): A Global, Randomised, Placebo-controlled, Phase 3 Study,” The Lancet Oncology 24, no. 5 (2023): 483-495.

[103] L. Shen, K. Kato, S. B. Kim, et al., “Tislelizumab versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 40, no. 26 (2022): 3065-3076.

[104] H. Luo, J. Lu, Y. Bai, et al., “Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial,” JAMA 326, no. 10 (2021): 916-925.

[105] S. Park, D. Oh, Y. L. Choi, et al., “Durvalumab and Tremelimumab With Definitive Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma,” Cancer 128, no. 11 (2022): 2148-2158.

[106] Y. Zhu, J. Wen, Q. Li, et al., “Toripalimab Combined with Definitive Chemoradiotherapy in Locally Advanced Oesophageal Squamous Cell Carcinoma (EC-CRT-001): A Single-arm, Phase 2 Trial,” The Lancet Oncology 24, no. 4 (2023): 371-382.

[107] M. A. Shah, J. Bennouna, T. Doi, et al., “KEYNOTE-975 Study Design: A Phase III Study of Definitive Chemoradiotherapy plus Pembrolizumab in Patients with Esophageal Carcinoma,” Future Oncology 17, no. 10 (2021): 1143-1153.

[108] K. A. Goodman, X.u R-H, I. Chau, et al., SKYSCRAPER-07: A Phase III, Randomized, Double-blind, Placebo-controlled Study of Atezolizumab with or without Tiragolumab in Patients with Unresectable ESCC Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy. (American Society of Clinical Oncology, 2022).

[109] C.-H. Hsu, Z. Lu, S. Gao, et al., SKYSCRAPER-08: A Phase III, Randomized, Double-blind, Placebo-controlled Study of First-line (1L) Tiragolumab (tira)+ Atezolizumab (atezo) and Chemotherapy (CT) in Patients (pts) with Esophageal Squamous Cell Carcinoma (ESCC). (American Society of Clinical Oncology, 2024).

[110] T. Kojima, M. A. Shah, K. Muro, et al., “Randomized Phase III KEYNOTE-181 Study of Pembrolizumab versus Chemotherapy in Advanced Esophageal Cancer,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 38, no. 35 (2020): 4138-4148.

[111] T. K. Choueiri, T. Powles, M. Burotto, et al., “Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma,” The New England Journal of Medicine 384, no. 9 (2021): 829-841.

[112] D. Brazel and S. I. Ou, “The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching up with Current Scientific View of Immunotherapy in Never-Smoker Predominant Actionable Driver Mutation Positive NSCLC?,” Lung Cancer (Auckl) 14 (2023): 63-69.

[113] Ancevski Hunter K, M. A. Socinski and L. C. Villaruz, “PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer,” Molecular Diagnosis & Therapy 22, no. 1 (2018): 1-10.

[114] S. Gandini, D. Massi, and M. Mandalà, “PD-L1 Expression in Cancer Patients Receiving Anti PD-1/PD-L1 Antibodies: A Systematic Review and Meta-analysis,” Critical Reviews in Oncology/Hematology 100 (2016): 88-98.

[115] T. S. K. Mok, Y. L. Wu, I. Kudaba, et al., “Pembrolizumab versus Chemotherapy for Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic Non-small-cell Lung Cancer (KEYNOTE-042): A Randomised, Open-label, Controlled, Phase 3 Trial,” Lancet (London, England) 393, no. 10183 (2019): 1819-1830.

[116] J. Jassem, F. de Marinis, G. Giaccone, et al., “Updated Overall Survival Analysis From IMpower110: Atezolizumab versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLC,” Journal of Thoracic Oncology 16, no. 11 (2021): 1872-1882.

[117] M. Özgüroğlu, S. Kilickap, A. Sezer, et al., “First-Line Cemiplimab Monotherapy and Continued Cemiplimab Beyond Progression Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 50% or More (EMPOWER-Lung 1): 35-Month Follow-up From a Mutlicentre, Open-label, Randomised, Phase 3 Trial,” The Lancet Oncology 24, no. 9 (2023): 989-1001.

[118] R. S. Herbst, P. Baas, D. W. Kim, et al., “Pembrolizumab versus Docetaxel for Previously Treated, PD-L1-positive, Advanced Non-small-cell Lung Cancer (KEYNOTE-010): A Randomised Controlled Trial,” Lancet (London, England) 387, no. 10027 (2016): 1540-1550.

[119] A. Rittmeyer, F. Barlesi, D. Waterkamp, et al., “Atezolizumab versus Docetaxel in Patients with Previously Treated Non-small-cell Lung Cancer (OAK): A Phase 3, Open-label, Multicentre Randomised Controlled Trial,” Lancet (London, England) 389, no. 10066 (2017): 255-265.

[120] H. West, M. McCleod, M. Hussein, et al., “Atezolizumab in Combination with Carboplatin plus Nab-paclitaxel Chemotherapy Compared with Chemotherapy Alone as First-line Treatment for Metastatic Non-squamous Non-small-cell Lung Cancer (IMpower130): A Multicentre, Randomised, Open-label, Phase 3 Trial,” The Lancet Oncology 20, no. 7 (2019): 924-937.

[121] S. Gadgeel, D. Rodríguez-Abreu, G. Speranza, et al., “Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 38, no. 14 (2020): 1505-1517.

[122] S. Novello, D. M. Kowalski, A. Luft, et al., “Pembrolizumab plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 41, no. 11 (2023): 1999-2006.

[123] M. A. Socinski, M. Nishio, R. M. Jotte, et al., “IMpower150 Final Overall Survival Analyses for Atezolizumab plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC,” Journal of Thoracic Oncology 16, no. 11 (2021): 1909-1924.

[124] J. R. Brahmer, J. S. Lee, T. E. Ciuleanu, et al., “Five-Year Survival Outcomes With Nivolumab plus Ipilimumab versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 41, no. 6 (2023): 1200-1212.

[125] M. A. Socinski, R. M. Jotte, F. Cappuzzo, et al., “Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC,” The New England Journal of Medicine 378, no. 24 (2018): 2288-2301.

[126] D. R. Gandara, J. von Pawel, J. Mazieres, et al., “Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study,” Journal of Thoracic Oncology 13, no. 12 (2018): 1906-1918.

[127] R. S. Heist, M. J. Guarino, G. Masters, et al., “Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 35, no. 24 (2017): 2790-2797.

[128] F. Ghiringhelli, L. Doucet, P. Barre, et al., “GALLANT-1: Galectin-3 (Gal-3) Inhibitor GB1211 plus Atezolizumab (atezo) in Patients with Non-small Cell Lung Cancer (NSCLC)—A Randomized, Double-blind Trial,” Journal of Clinical Oncology 40 (2022).

[129] M.-J. Ahn, K. Tanaka, L. Paz-Ares, et al., “Datopotamab Deruxtecan versus Docetaxel for Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer: The Randomized, Open-label Phase III TROPION-Lung01 Study,” Journal of Clinical Oncology (2024): JCO-24-01544.

[130] P. Savas, R. Salgado, C. Denkert, et al., “Clinical Relevance of Host Immunity in Breast Cancer: From TILs to the Clinic,” Nature Reviews Clinical Oncology 13, no. 4 (2016): 228-241.

[131] J. Isaacs, C. Anders, H. McArthur, and J. Force, “Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer,” Current Treatment Options in Oncology 22, no. 5 (2021): 38.

[132] C. Desmedt, B. Haibe-Kains, P. Wirapati, et al., “Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes,” Clinical Cancer Research: an Official Journal of the 14, no. 16 (2008): 5158-5165.

[133] R. Nanda, L. Q. Chow, E. C. Dees, et al., “Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 34, no. 21 (2016): 2460-2467.

[134] L. A. Emens, C. Cruz, J. P. Eder, et al., “Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study,” JAMA Oncology 5, no. 1 (2019): 74-82.

[135] P. Schmid, S. Adams, H. S. Rugo, et al., “Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer,” The New England Journal of Medicine 379, no. 22 (2018): 2108-2121.

[136] W. J. Gradishar, M. S. Moran, J. Abraham, et al., “NCCN Guidelines® Insights: Breast Cancer, Version 4.2021,” Journal of the National Comprehensive Cancer Network: JNCCN 19, no. 5 (2021): 484-493.

[137] P. Schmid, J. Cortes, L. Pusztai, et al., “Pembrolizumab for Early Triple-Negative Breast Cancer,” The New England Journal of Medicine 382, no. 9 (2020): 810-821.

[138] R. Nanda, M. C. Liu, C. Yau, et al., “Effect of Pembrolizumab plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial,” JAMA Oncology 6, no. 5 (2020): 676-684.

[139] J. Huober, C. H. Barrios, N. Niikura, et al., “Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 40, no. 25 (2022): 2946-2956.

[140] L. A. Emens, F. J. Esteva, M. Beresford, et al., “Trastuzumab Emtansine Plus Atezolizumab Versus Trastuzumab Emtansine Plus Placebo in Previously Treated, HER2-positive Advanced Breast Cancer (KATE2): A Phase 2, Multicentre, Randomised, Double-Blind Trial,” The Lancet Oncology 21, no. 10 (2020): 1283-1295.

[141] H. K. Ahn, S. H. Sim, K. J. Suh, et al., “Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical Trial,” JAMA Oncology 8, no. 9 (2022): 1271-1277.

[142] H. S. Rugo, J. P. Delord, S. A. Im, et al., “Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer,” Clinical Cancer Research: an Official Journal of the 24, no. 12 (2018): 2804-2811.

[143] D. Wu, S. Tang, R. Ye, et al., “Case Report: Long-Term Response to Pembrolizumab Combined With Endocrine Therapy in Metastatic Breast Cancer Patients With Hormone Receptor Expression,” Frontiers in Immunology 12 (2021): 610149.

[144] Y. Yuan, J. S. Lee, S. E. Yost, et al., “Phase I/II Trial of Palbociclib, Pembrolizumab and Letrozole in Patients with Hormone Receptor-positive Metastatic Breast Cancer,” European Journal of Cancer (Oxford, England: 1990) 154 (2021): 11-20.

[145] S. Vinayak, S. M. Tolaney, L. Schwartzberg, et al., “Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer,” JAMA Oncology 5, no. 8 (2019): 1132-1140.

[146] S. M. Domchek, S. Postel-Vinay, S. A. Im, et al., “Olaparib and Durvalumab in Patients With Germline BRCA-Mutated Metastatic Breast Cancer (MEDIOLA): An Open-Label, Multicentre, Phase 1/2, Basket Study,” The Lancet Oncology 21, no. 9 (2020): 1155-1164.

[147] Y. Song, L. Bugada, R. Li, et al., “Albumin Nanoparticle Containing a PI3Kγ Inhibitor and Paclitaxel in Combination with α-PD1 Induces Tumor Remission of Breast Cancer in Mice,” Science Translational Medicine 14, no. 643 (2022): eabl3649.

[148] P. Schmid, N. C. Turner, C. H. Barrios, et al., “First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results,” Clinical Cancer Research: an Official Journal of the 30, no. 4 (2024): 767-778.

[149] Y. Liu, Y. Hu, J. Xue, et al., “Advances in Immunotherapy for Triple-negative Breast Cancer,” Molecular Cancer 22, no. 1 (2023): 145.

[150] P. Dasgupta, C. Henshaw, D. R. Youlden, P. J. Clark, J. F. Aitken, and P. D. Baade, “Global Trends in Incidence Rates of Primary Adult Liver Cancers: A Systematic Review and Meta-Analysis. Systematic Review,” Frontiers in Oncology 10 (2020).

[151] B. Sangro, C. Gomez-Martin, M. de la Mata, et al., “A Clinical Trial of CTLA-4 Blockade With Tremelimumab in Patients With Hepatocellular Carcinoma and Chronic Hepatitis C,” Journal of Hepatology 59, no. 1 (2013): 81-88.

[152] J. M. Llovet, S. Ricci, V. Mazzaferro, et al., “Sorafenib in Advanced Hepatocellular Carcinoma,” The New England Journal of Medicine 359, no. 4 (2008): 378-390.

[153] Nivolumab Approved for Liver Cancer. Cancer Discovery 2017; 7(11): Of3.

[154] A. B. El-Khoueiry, B. Sangro, T. Yau, et al., “Nivolumab in Patients with Advanced Hepatocellular Carcinoma (CheckMate 040): An Open-label, Non-comparative, Phase 1/2 Dose Escalation and Expansion Trial,” Lancet (London, England) 389, no. 10088 (2017): 2492-2502.

[155] M. Kudo, A. Matilla, A. Santoro, et al., “CheckMate 040 Cohort 5: A Phase I/II Study of Nivolumab in Patients With Advanced Hepatocellular Carcinoma and Child-Pugh B Cirrhosis,” Journal of Hepatology 75, no. 3 (2021): 600-609.

[156] B. Sangro, I. Melero, S. Wadhawan, et al., “Association of Inflammatory Biomarkers With Clinical Outcomes in Nivolumab-Treated Patients With Advanced Hepatocellular Carcinoma,” Journal of Hepatology 73, no. 6 (2020): 1460-1469.

[157] T. Yau, J. W. Park, R. S. Finn, et al., “Nivolumab versus sorafenib in Advanced Hepatocellular Carcinoma (CheckMate 459): A Randomised, Multicentre, Open-label, Phase 3 Trial,” The Lancet Oncology 23, no. 1 (2022): 77-90.

[158] R. S. Finn, B. Y. Ryoo, P. Merle, et al., “Pembrolizumab as Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 38, no. 3 (2020): 193-202.

[159] M. Kudo, H. Y. Lim, A. L. Cheng, et al., “Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial,” Liver Cancer 10, no. 3 (2021): 275-284.

[160] S. Qin, W. Fang, Z. Ren, et al., “A Phase 3 Study of Pembrolizumab versus Placebo for Previously Treated Patients from Asia with Hepatocellular Carcinoma: Health-Related Quality of Life Analysis from KEYNOTE-394,” Liver Cancer 13, no. 4 (2024): 389-400.

[161] S. Qin, Z. Ren, Z. Meng, et al., “Camrelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma: A Multicentre, Open-label, Parallel-group, Randomised, Phase 2 Trial,” The Lancet Oncology 21, no. 4 (2020): 571-580.

[162] B. Xu and H. C. Sun, “Camrelizumab: An Investigational Agent for Hepatocellular Carcinoma,” Expert Opinion on Investigational Drugs 31, no. 4 (2022): 337-346.

[163] Z. Ren, M. Ducreux, G. K. Abou-Alfa, et al., “Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial,” Liver Cancer 12, no. 1 (2023): 72-84.

[164] S. Qin, M. Kudo, T. Meyer, et al., “Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial,” JAMA Oncology 9, no. 12 (2023): 1651-1659.

[165] S. L. Chan, B. Y. Ryoo, F. Mo, et al., “Multicentre Phase II Trial of Cabozantinib in Patients with Hepatocellular Carcinoma after Immune Checkpoint Inhibitor Treatment,” Journal of Hepatology 81, no. 2 (2024): 258-264.

[166] L. Rimassa, R. S. Finn, and B. Sangro, “Combination Immunotherapy for Hepatocellular Carcinoma,” Journal of Hepatology 79, no. 2 (2023): 506-515.

[167] A. X. Zhu, F. Dayyani, C. J. Yen, et al., “Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma,” Clinical Cancer Research: an Official Journal of the 28, no. 16 (2022): 3537-3545.

[168] Z. Ren, J. Xu, Y. Bai, et al., “Sintilimab plus a Bevacizumab Biosimilar (IBI305) versus Sorafenib in Unresectable Hepatocellular Carcinoma (ORIENT-32): A Randomised, Open-label, Phase 2-3 Study,” The Lancet Oncology 22, no. 7 (2021): 977-990.

[169] T. Li, S. Guo, C. Xu, et al., “Integrated Single-cell Transcriptome and TCR Profiles of Hepatocellular Carcinoma Highlight the Convergence on Interferon Signaling during Immunotherapy,” Journal for Immunotherapy of Cancer 12, no. 11 (2024).

[170] R. K. Kelley, L. Rimassa, A. L. Cheng, et al., “Cabozantinib plus Atezolizumab versus Sorafenib for Advanced Hepatocellular Carcinoma (COSMIC-312): A Multicentre, Open-label, Randomised, Phase 3 Trial,” The Lancet Oncology 23, no. 8 (2022): 995-1008.

[171] J. M. Llovet, M. Kudo, P. Merle, et al., “Lenvatinib Plus Pembrolizumab Versus Lenvatinib Plus Placebo for Advanced Hepatocellular Carcinoma (LEAP-002): A Randomised, Double-Blind, Phase 3 Trial,” The Lancet Oncology 24, no. 12 (2023): 1399-1410.

[172] S. Qin, S. L. Chan, S. Gu, et al., “Camrelizumab Plus Rivoceranib Versus Sorafenib as First-Line Therapy for Unresectable Hepatocellular Carcinoma (CARES-310): A Randomised, Open-Label, International Phase 3 Study,” Lancet (London, England) 402, no. 10408 (2023): 1133-1146.

[173] A. Vogel, S. L. Chan, Z. Ren, et al., Camrelizumab Plus Rivoceranib vs Sorafenib as First-Line Therapy for Unresectable Hepatocellular Carcinoma (uHCC): Final Overall Survival Analysis of the Phase 3 CARES-310 Study. (American Society of Clinical Oncology, 2024).

[174] D. Hsiehchen, M. S. Beg, R. Kainthla, et al., “The Phosphatidylserine Targeting Antibody Bavituximab plus Pembrolizumab in Unresectable Hepatocellular Carcinoma: A Phase 2 Trial,” Nature Communications 15, no. 1 (2024): 2178.

[175] C. Hsu, Y. F. Chang, C. J. Yen, Y. W. Xu, M. Dong, and Y. Z. Tong, “Combination of GT90001 and Nivolumab in Patients With Advanced Hepatocellular Carcinoma: A Multicenter, Single-arm, Phase 1b/2 Study,” BMC Medicine [Electronic Resource] 21, no. 1 (2023): 395.

[176] L. Meng, H. Li, Y. Ji, et al., “Efficacy, Safety, and Biomarker Analysis of TACE Combined with Lenvatinib plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Real-world Study,” Cancer Immunology, Immunotherapy 74, no. 1 (2024): 13.

[177] R. Lencioni, M. Kudo, J. Erinjeri, et al., EMERALD-1: A Phase 3, Randomized, Placebo-Controlled Study of Transarterial Chemoembolization Combined With Durvalumab With or Without Bevacizumab in Participants With Unresectable Hepatocellular Carcinoma Eligible for Embolization. (American Society of Clinical Oncology, 2024).

[178] Y. Yuan, J. Qiu, Z. Huang, et al., PD-1 Inhibitor (sintilimab) and Lenvatinib plus TACE-HAIC as Conversion Therapy for Initially Unresectable HCC: A Single-arm, Phase 2 Clinical Trial (PLATIC). (American Society of Clinical Oncology, 2024).

[179] M. Shah and C. McManus, “The Role of Radiofrequency Ablation in Benign and Malignant Thyroid Nodules,” Surgical Clinics of North America 104, no. 4 (2024): 779-789.

[180] M. H. den Brok, R. P. Sutmuller, R. van der Voort, et al., “In Situ Tumor Ablation Creates an Antigen Source for the Generation of Antitumor Immunity,” Cancer Research 64, no. 11 (2004): 4024-4029.

[181] K. J. Kim, J. H. Kim, S. J. Lee, E. J. Lee, E. C. Shin, and J. Seong, “Radiation Improves Antitumor Effect of Immune Checkpoint Inhibitor in Murine Hepatocellular Carcinoma Model,” Oncotarget 8, no. 25 (2017): 41242-41255.

[182] D. Tai, K. Loke, A. Gogna, et al., “Radioembolisation With Y90-Resin Microspheres Followed by Nivolumab for Advanced Hepatocellular Carcinoma (CA 209-678): A Single Arm, Single Centre, Phase 2 Trial,” The Lancet Gastroenterology & Hepatology 6, no. 12 (2021): 1025-1035.

[183] S. Yu, M. Yu, B. Keane, et al., “A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma,” The Oncologist 29, no. 3 (2024): 270-e413.

[184] Z. Lai, M. He, X. Bu, et al., “Lenvatinib, toripalimab plus Hepatic Arterial Infusion Chemotherapy in Patients with High-risk Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Phase II Trial,” European Journal of Cancer (Oxford, England: 1990) 174 (2022): 68-77.

[185] T. Q. Zhang, Z. J. Geng, M. X. Zuo, et al., “Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and Hepatic Artery Infusion Chemotherapy for Hepatocellular Carcinoma in Barcelona Clinic Liver Cancer Stage C (TRIPLET): A Phase II Study,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 413.

[186] J. D. Gordan, E. B. Kennedy, G. K. Abou-Alfa, et al., “Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 42, no. 15 (2024): 1830-1850.

[187] M. Nikoo, F. Rabiee, H. Mohebbi, et al., “Nivolumab Plus Ipilimumab Combination Therapy in Cancer: Current Evidence to Date,” International Immunopharmacology 117 (2023): 109881.

[188] P. R. Galle, T. Decaens, M. Kudo, et al., Nivolumab (NIVO) Plus Ipilimumab (IPI) vs Lenvatinib (LEN) or Sorafenib (SOR) as First-Line Treatment for Unresectable Hepatocellular Carcinoma (uHCC): First Results From CheckMate 9DW. (American Society of Clinical Oncology, 2024).

[189] B. Sangro, S. L. Chan, R. K. Kelley, et al., “Four-year Overall Survival Update From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma,” Annals of Oncology: Official Journal of the European Society for Medical Oncology 35, no. 5 (2024): 448-457.

[190] S. Qin, J. Fan, F. Yang, et al., “LBA38 Iparomlimab and Tuvonralimab (QL1706) With Bevacizumab and/or Chemotherapy in First-line (1L) Treatment of Advanced Hepatocellular Carcinoma (aHCC): A Randomized, Open-Label, Phase II/III Study (DUBHE-H-308),” Annals of Oncology 35 (2024): S1229-S1230.

[191] Y. Tu, H. Wu, C. Zhong, et al., “Pharmacological Activation of STAT1-GSDME Pyroptotic Circuitry Reinforces Epigenetic Immunotherapy for Hepatocellular Carcinoma,” Gut (2024).

[192] J. Cai, L. Song, F. Zhang, et al., “Targeting SRSF10 Might Inhibit M2 Macrophage Polarization and Potentiate anti-PD-1 Therapy in Hepatocellular Carcinoma,” Cancer Communications 44, no. 11 (2024): 1231-1260.

[193] X. Zhou, Z. Chen, Y. Yu, et al., “Increases in 4-Acetaminobutyric Acid Generated by Phosphomevalonate Kinase Suppress CD8(+) T Cell Activation and Allow Tumor Immune Escape,” Advanced Science 11, no. 43 (2024): e2403629.

[194] J. Cao, B. Su, C. Zhang, et al., “Degradation of PARP1 by MARCHF3 in Tumor Cells Triggers cCAS-STING Activation in Dendritic Cells to Regulate Antitumor Immunity in Hepatocellular Carcinoma,” Journal for Immunotherapy of Cancer 12, no. 11 (2024).

[195] S. Morita, P. J. Lei, K. Shigeta, et al., “Combination CXCR4 and PD1 Blockade Enhances Intratumoral Dendritic Cell Activation and Immune Responses against Hepatocellular Carcinoma,” Cancer Immunology Research (2024).

[196] X. Xiang, K. Wang, H. Zhang, et al., “Blocking CX3CR1+ Tumor-Associated Macrophages Enhances the Efficacy of Anti-PD1 Therapy in Hepatocellular Carcinoma,” Cancer Immunology Research 12, no. 11 (2024): 1603-1620.

[197] R. J. Sylvester, W. Oosterlinck, S. Holmang, et al., “Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation?,” European Urology 69, no. 2 (2016): 231-244.

[198] I. H. Kim and H. J. Lee, “Perioperative Systemic Treatment for Muscle-Invasive Bladder Cancer: Current Evidence and Future Perspectives,” International Journal of Molecular Sciences 22, no. 13 (2021).

[199] B. Szabados, M. Kockx, Z. J. Assaf, et al., “Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder,” European Urology 82, no. 2 (2022): 212-222.

[200] R. J. Sylvester, M. A. van der, and D. L. Lamm, “Intravesical Bacillus Calmette-Guerin Reduces the Risk of Progression in Patients With Superficial Bladder Cancer: A Meta-Analysis of the Published Results of Randomized Clinical Trials,” Journal of Urology 168, no. 5 (2002): 1964-1970.

[201] A. V. Balar, A. M. Kamat, G. S. Kulkarni, et al., “Pembrolizumab Monotherapy for the Treatment of High-risk Non-muscle-invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-label, Single-arm, Multicentre, Phase 2 Study,” The Lancet Oncology 22, no. 7 (2021): 919-930.

[202] A. Necchi, A. Anichini, D. Raggi, et al., “Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 36, no. 34 (2018): 3353-3360.

[203] T. Powles, M. Kockx, A. Rodriguez-Vida, et al., “Clinical Efficacy and Biomarker Analysis of Neoadjuvant Atezolizumab in Operable Urothelial Carcinoma in the ABACUS Trial,” Nature Medicine 25, no. 11 (2019): 1706-1714.

[204] D. F. Bajorin, J. A. Witjes, J. E. Gschwend, et al., “Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma,” The New England Journal of Medicine 384, no. 22 (2021): 2102-2114.

[205] J. Bellmunt, M. Hussain, J. E. Gschwend, et al., “Adjuvant Atezolizumab versus Observation in Muscle-invasive Urothelial Carcinoma (IMvigor010): A Multicentre, Open-label, Randomised, Phase 3 Trial,” The Lancet Oncology 22, no. 4 (2021): 525-537.

[206] T. Powles, S. H. Park, E. Voog, et al., “Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma,” The New England Journal of Medicine 383, no. 13 (2020): 1218-1230.

[207] A. V. Balar, M. D. Galsky, J. E. Rosenberg, et al., “Atezolizumab as First-line Treatment in Cisplatin-ineligible Patients with Locally Advanced and Metastatic Urothelial Carcinoma: A Single-arm, Multicentre, Phase 2 Trial,” Lancet (London, England) 389, no. 10064 (2017): 67-76.

[208] T. Powles, T. Csőszi, M. Özgüroğlu, et al., “Pembrolizumab Alone or Combined with Chemotherapy versus Chemotherapy as First-line Therapy for Advanced Urothelial Carcinoma (KEYNOTE-361): A Randomised, Open-label, Phase 3 Trial,” The Lancet Oncology 22, no. 7 (2021): 931-945.

[209] J. Bellmunt, R. de Wit, D. J. Vaughn, et al., “Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma,” The New England Journal of Medicine 376, no. 11 (2017): 1015-1026.

[210] P. Sharma, M. Retz, A. Siefker-Radtke, et al., “Nivolumab in Metastatic Urothelial Carcinoma after Platinum Therapy (CheckMate 275): A Multicentre, Single-arm, Phase 2 Trial,” The Lancet Oncology 18, no. 3 (2017): 312-322.

[211] A. B. Apolo, J. R. Infante, A. Balmanoukian, et al., “Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, in Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 35, no. 19 (2017): 2117-2124.

[212] C. T. Garnett, C. Palena, M. Chakraborty, K. Y. Tsang, J. Schlom, and J. W. Hodge, “Sublethal Irradiation of human Tumor Cells Modulates Phenotype Resulting in Enhanced Killing by Cytotoxic T Lymphocytes,” Cancer Research 64, no. 21 (2004): 7985-7994.

[213] M. Larroquette, C. Domblides, F. Lefort, et al., “Combining Immune Checkpoint Inhibitors with Chemotherapy in Advanced Solid Tumours: A Review,” European Journal of Cancer (Oxford, England: 1990) 158 (2021): 47-62.

[214] S. Gupta, G. Sonpavde, C. J. Weight, et al., Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of Nivolumab, Gemcitabine, and Cisplatin in Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy. (American Society of Clinical Oncology, 2020).

[215] T. Lin, K. Li, J. Fan, et al., Interim Results from a Multicenter Clinical Study of Tislelizumab Combined with Gemcitabine and Cisplatin as Neoadjuvant Therapy for Patients with cT2-T4aN0M0 MIBC. (American Society of Clinical Oncology, 2022).

[216] N. van Dijk, A. Gil-Jimenez, K. Silina, et al., “Preoperative Ipilimumab plus Nivolumab in Locoregionally Advanced Urothelial Cancer: The NABUCCO Trial,” Nature Medicine 26, no. 12 (2020): 1839-1844.

[217] M. S. van der Heijden, G. Sonpavde, T. Powles, et al., “Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma,” The New England Journal of Medicine 389, no. 19 (2023): 1778-1789.

[218] M. De Santis, J. Bellmunt, G. Mead, et al., “Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients with Advanced Urothelial Cancer Who Are Unfit for Cisplatin-based Chemotherapy: EORTC Study 30986,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 30, no. 2 (2012): 191-199.

[219] C. J. Hoimes, T. W. Flaig, M. I. Milowsky, et al., “Enfortumab Vedotin plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 41, no. 1 (2023): 22-31.

[220] L. Zhou, H. Xu, S. Li, et al., Study RC48-C014: Preliminary Results of RC48-ADC Combined with toripalimab in Patients with Locally Advanced or Metastatic Urothelial Carcinoma. (American Society of Clinical Oncology, 2022).

[221] K. E. Pauken, M. Dougan, N. R. Rose, A. H. Lichtman, and A. H. Sharpe, “Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities,” Trends in Immunology 40, no. 6 (2019): 511-523.

[222] D. Y. Wang, J. E. Salem, J. V. Cohen, et al., “Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis,” JAMA Oncology 4, no. 12 (2018): 1721-1728.

[223] M. A. Postow, R. Sidlow, and M. D. Hellmann, “Immune-Related Adverse Events Associated with Immune Checkpoint Blockade,” The New England Journal of Medicine 378, no. 2 (2018): 158-168.

[224] Y. H. Chen, T. Kovács, P. Ferdinandy, and Z. V. Varga, “Treatment Options for Immune-related Adverse Events Associated with Immune Checkpoint Inhibitors,” British Journal of Pharmacology (2024).

[225] F. S. Hodi, S. J. O'Day, D. F. McDermott, et al., “Improved Survival with ipilimumab in Patients with Metastatic Melanoma,” The New England Journal of Medicine 363, no. 8 (2010): 711-723.

[226] A. Bertrand, M. Kostine, T. Barnetche, M. E. Truchetet, and T. Schaeverbeke, “Immune Related Adverse Events Associated with Anti-CTLA-4 Antibodies: Systematic Review and Meta-analysis,” BMC Medicine [Electronic Resource] 13 (2015): 211.

[227] J. Larkin, V. Chiarion-Sileni, R. Gonzalez, et al., “Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma,” The New England Journal of Medicine 373, no. 1 (2015): 23-34.

[228] S. Baxi, A. Yang, R. L. Gennarelli, et al., “Immune-related Adverse Events for Anti-PD-1 and Anti-PD-L1 Drugs: Systematic Review and Meta-analysis,” BMJ 360 (2018): k793.

[229] P. Xing, F. Zhang, G. Wang, et al., “Incidence Rates of Immune-related Adverse Events and Their Correlation with Response in Advanced Solid Tumours Treated with NIVO or NIVO+IPI: A Systematic Review and Meta-analysis,” Journal for Immunotherapy of Cancer 7, no. 1 (2019): 341.

[230] O. E. Rahma, J. E. Reuss, A. Giobbie-Hurder, et al., “Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors,” Clinical Cancer Research: an Official Journal of the American Association for Cancer Research 27, no. 2 (2021): 485-491.

[231] X. Liang, H. Xiao, H. Li, X. Chen, and Y. Li, “Adverse Events Associated with Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer: A Safety Analysis of Clinical Trials and FDA Pharmacovigilance System,” Frontiers in Immunology 15 (2024): 1396752.

[232] A. Markham and S. Duggan, “Cemiplimab: First Global Approval,” Drugs 78, no. 17 (2018): 1841-1846.

[233] O. Akinboro, E. Larkins, L. H. Pai-Scherf, et al., “FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1-High NSCLC,” Clinical Cancer Research: an Official Journal of the 28, no. 11 (2022): 2221-2228.

[234] A. J. Stratigos, A. Sekulic, K. Peris, et al., “Cemiplimab in Locally Advanced Basal Cell Carcinoma after Hedgehog Inhibitor Therapy: An Open-label, Multi-centre, Single-arm, Phase 2 Trial,” The Lancet Oncology 22, no. 6 (2021): 848-857.

[235] A. Oaknin, B. Pothuri, L. Gilbert, et al., “Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study,” Clinical Cancer Research: an Official Journal of the American Association for Cancer Research 29, no. 22 (2023): 4564-4574.

[236] T. André, D. Berton, G. Curigliano, et al., “Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial,” JAMA Network Open 6, no. 11 (2023): e2341165.

[237] L. N. Mathieu, E. Larkins, A. K. Sinha, et al., “FDA Approval Summary: Atezolizumab as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Stage II to IIIA NSCLC,” Clinical Cancer Research: an Official Journal of the American Association for Cancer Research 29, no. 16 (2023): 2973-2978.

[238] L. Mathieu, S. Shah, L. Pai-Scherf, et al., “FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer,” The Oncologist 26, no. 5 (2021): 433-438.

[239] P. Narayan, S. Wahby, J. J. Gao, et al., “FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1,” Clinical Cancer Research: an Official Journal of the 26, no. 10 (2020): 2284-2289.

[240] J. M. Llovet, F. Castet, M. Heikenwalder, et al., “Immunotherapies for Hepatocellular Carcinoma,” Nature Reviews Clinical Oncology 19, no. 3 (2022): 151-172.

[241] F. Yang, C. Shay, M. Abousaud, et al., “Patterns of Toxicity Burden for FDA-approved Immune Checkpoint Inhibitors in the United States,” Journal of Experimental & Clinical Cancer Research 42, no. 1 (2023): 4.

[242] S. V. Liu, M. Reck, A. S. Mansfield, et al., “Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133),” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 39, no. 6 (2021): 619-630.

[243] D. Miles, J. Gligorov, F. André, et al., “Primary Results from IMpassion131, a Double-blind, Placebo-controlled, Randomised Phase III Trial of First-line Paclitaxel with or without Atezolizumab for Unresectable Locally Advanced/Metastatic Triple-negative Breast Cancer,” Annals of Oncology: Official Journal of the European Society for Medical Oncology 32, no. 8 (2021): 994-1004.

[244] A. Akinleye and Z. Rasool, “Immune Checkpoint Inhibitors of PD-L1 as Cancer Therapeutics,” Journal of Hematology & Oncology 12, no. 1 (2019): 92.

[245] B. Sangro, P. R. Galle, R. K. Kelley, et al., “Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 42, no. 23 (2024): 2790-2799.

[246] S. J. Antonia, A. Villegas, D. Daniel, et al., “Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC,” The New England Journal of Medicine 379, no. 24 (2018): 2342-2350.

[247] H. A. Burris, T. Okusaka, A. Vogel, et al., “Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer (TOPAZ-1): Patient-reported Outcomes from a Randomised, Double-blind, Placebo-controlled, Phase 3 Trial,” The Lancet Oncology 25, no. 5 (2024): 626-635.

[248] H. A. Tawbi, D. Schadendorf, E. J. Lipson, et al., “Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma,” The New England Journal of Medicine 386, no. 1 (2022): 24-34.

[249] B. A. Hijaz, N. Braun, K. Reynolds, Y. R. Semenov, N. R. LeBoeuf, and C. ST, “Nivolumab/relatlimab-associated Cutaneous Immune-related Adverse Events in Patients Treated for Advanced Melanoma: A Multi-center Retrospective Cohort Study,” Journal of the American Academy of Dermatology (2025).

[250] P. G. M. de Gooyer, Y. L. Verschoor, L. D. W. van den Dungen, et al., “Neoadjuvant nivolumab and Relatlimab in Locally Advanced MMR-deficient Colon Cancer: A Phase 2 Trial,” Nature Medicine 30, no. 11 (2024): 3284-3290.

[251] K. Wright, “FDA Approves Nivolumab plus Ipilimumab for the Treatment of Advanced HCC,” Oncology (Williston Park) 34, no. 4 (2020).

[252] A. K. Maloney, A. Giobbie-Hurder, N. Katukota, et al., “Nivolumab Maintenance Improves Overall Survival of Patients with Advanced Melanoma Who Experience Severe Immune-related Adverse Events on nivolumab plus ipilimumab,” Journal for Immunotherapy of Cancer 12, no. 8 (2024).

[253] C. Y. Chang, H. Park, D. C. Malone, et al., “Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis,” JAMA Network Open 3, no. 3 (2020): e201611.

[254] P. Rochigneux, A. Bertucci, E. Loir, et al., “Case Report: A Severe Myositis Mimicking Bulbar Palsy after Administration of Immune Checkpoint Inhibitors,” Frontiers in Immunology 16 (2025): 1496427.

[255] S. Asby, L. E. Thompson, M. Goedken, et al., “Pathological Findings of Immunotherapy-induced Nephrotoxicity in a Humanized Immune System Mouse Model,” Kidney International (2025).

[256] M. Shatila, H. C. Zhang, A. Shirwaikar Thomas, et al., “Systematic Review of Immune Checkpoint Inhibitor-related Gastrointestinal, Hepatobiliary, and Pancreatic Adverse Events,” Journal for Immunotherapy of Cancer 12, no. 11 (2024).

[257] B. Wang, S. Zhuang, S. Lin, et al., “Analysis of Risk Factors for Immune Checkpoint Inhibitor-associated Liver Injury: A Retrospective Analysis Based on Clinical Study and Real-world Data,” Hepatology International (2025).

[258] Q. Fang, Y. Qian, Z. Xie, H. Zhao, Y. Zheng, and D. Li, “Predictors of Severity and Onset Timing of Immune-related Adverse Events in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Analysis,” Frontiers in Immunology 16 (2025): 1508512.

[259] B. H. Esen, S. N. Bektas, U. Topcu, et al., “Immune-related Adverse Events in Older Adults Receiving Immune Checkpoint Inhibitors: A Comprehensive Analysis of the Food and Drug Administration Adverse Event Reporting System,” Age and Ageing 54, no. 1 (2025).

[260] X. Zhang, B. Zhang, D. Li, et al., “Peripheral Blood Cell Counts as Predictors of Immune-related Adverse Events in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis,” Frontiers in Immunology 16 (2025): 1528084.

[261] A. Ezdoglian, A. S. M. Tsang, F. Khodadust, et al., “Monocyte-related Markers as Predictors of Immune Checkpoint Inhibitor Efficacy and Immune-related Adverse Events: A Systematic Review and Meta-analysis,” Cancer and Metastasis Reviews 44, no. 1 (2025): 35.

[262] S. Rosnev, B. Sterner, P. Schiele, et al., “Reduced Monocytic IL10 Expression in PD1 Inhibitor-treated Patients Is a Harbinger of Severe Immune-related Adverse Events,” European Journal of Cancer (Oxford, England: 1990) 217 (2025): 115252.

[263] M. Altan, R. Li, Z. Li, et al., “High Peripheral T Cell Diversity Is Associated with Lower Risk of Toxicity and Superior Response to Dual Immune Checkpoint Inhibitor Therapy in Patients with Metastatic NSCLC,” Journal for Immunotherapy of Cancer 12, no. 12 (2024).

[264] J. P. Long, S. Singh, Y. Dong, C. Yee, and J. S. Lin, “Urine Proteomics Defines an Immune Checkpoint-associated Nephritis Signature,” Journal for Immunotherapy of Cancer 13, no. 1 (2025).

[265] R. Matsukane, S. Nakamura, H. Minami, et al., “Krebs von den Lungen-6 Surveillance in Immune Checkpoint Inhibitor-induced Pneumonitis,” Journal for Immunotherapy of Cancer 12, no. 12 (2024).

[266] Y. V. Huang, Y. Sun, H. Chou, et al., “Novel Therapeutic Approach Targeting CXCR3 to Treat Immunotherapy Myocarditis,” Circulation Research 136, no. 5 (2025): 473-490.

[267] R. J. Verheijden, M. J. M. van Eijs, F. L. Paganelli, et al., “Gut Microbiome and Immune Checkpoint Inhibitor Toxicity,” European Journal of Cancer (Oxford, England: 1990) 216 (2025): 115221.

[268] J. Shang, D. M. Del Valle, G. J. Britton, et al., “Baseline Colitogenicity and Acute Perturbations of Gut Microbiota in Immunotherapy-related Colitis,” Journal of Experimental Medicine 222, no. 1 (2025).

[269] L. M. Braun, S. Giesler, G. Andrieux, et al., “Adiponectin Reduces Immune Checkpoint Inhibitor-induced Inflammation without Blocking Anti-tumor Immunity,” Cancer Cell 43, no. 2 (2025): 269-291. e19.

[270] Y. C. Shen, N. W. Chang, C. P. Yeh, et al., “Corticosteroid Premedication on Anti-tumor Effect of Immune Checkpoint Blockade in Murine Hepatocellular Carcinoma Models,” Journal for Immunotherapy of Cancer 13, no. 2 (2025).

[271] S. Pan and Z. Wang, “Antiviral Therapy Can Effectively Suppress irAEs in HBV Positive Hepatocellular Carcinoma Treated with ICIs: Validation Based on Multi Machine Learning,” Frontiers in Immunology 15 (2024): 1516524.

[272] R. Reschke, R. J. Sullivan, E. J. Lipson, A. H. Enk, T. F. Gajewski, and J. C. Hassel, “Targeting Molecular Pathways to Control Immune Checkpoint Inhibitor Toxicities,” Trends in Immunology 46, no. 1 (2025): 61-73.

[273] Z. Zhao, J. Fetse, U. F. Mamani, et al., “Development of a Peptide-based Tumor-activated Checkpoint Inhibitor for Cancer Immunotherapy,” Acta Biomaterialia 193 (2025): 484-497.

[274] C. H. Chiang, J. Song, K. Y. Chi, et al., “Glucagon-Like Peptide-1 Agonists Reduce Cardiovascular Events in Cancer Patients on Immune Checkpoint Inhibitors,” European Journal of Cancer (Oxford, England: 1990) 216 (2025): 115170.

[275] S. M. Knoche, A. C. Larson, B. H. Sliker, B. J. Poelaert, and J. C. Solheim, “The Role of Tumor Heterogeneity in Immune-tumor Interactions,” Cancer and Metastasis Reviews 40, no. 2 (2021): 377-389.

[276] B. Jayathilaka, F. Mian, F. Franchini, G. Au-Yeung, and M. IJ, “Cancer and Treatment Specific Incidence Rates of Immune-related Adverse Events Induced by Immune Checkpoint Inhibitors: A Systematic Review,” British Journal of Cancer (2024).

[277] H. Yamaguchi, J. M. Hsu, L. Sun, S. C. Wang, and H. MC, “Advances and Prospects of Biomarkers for Immune Checkpoint Inhibitors,” Cell Reports. Medicine 5, no. 7 (2024): 101621.

[278] I. C. Glitza, Y. D. Seo, C. N. Spencer, et al., “Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity,” Cancer Discovery 14, no. 7 (2024): 1161-1175.

[279] K. Nutsch, K. L. Banta, T. D. Wu, et al., “TIGIT and PD-L1 co-blockade Promotes Clonal Expansion of Multipotent, Non-exhausted Antitumor T Cells by Facilitating co-stimulation,” Nature Cancer 5, no. 12 (2024): 1834-1851.

[280] I. Melero, M. de, M. Luken, et al., “Neutralizing GDF-15 Can Overcome Anti-PD-1 and Anti-PD-L1 Resistance in Solid Tumours,” Nature (2024).

[281] J. A. Chesney, I. Puzanov, F. A. Collichio, et al., “Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone for Advanced Melanoma: 5-Year Final Analysis of a Multicenter, Randomized, Open-Label, Phase II Trial,” Journal for Immunotherapy of Cancer 11, no. 5 (2023).

[282] G. Zhang, Y. Chen, X. Huang, and T. Liang, “Cancer Immunotherapeutic Challenges from Autophagy-immune Checkpoint Reciprocal Regulation,” Trends in Cancer (2024).

[283] M. Yarchoan, E. J. Gane, T. U. Marron, et al., “Personalized Neoantigen Vaccine and Pembrolizumab in Advanced Hepatocellular Carcinoma: A Phase 1/2 Trial,” Nature Medicine 30, no. 4 (2024): 1044-1053.

[284] S. Tang, R. Tang, G. Chen, et al., “Personalized Neoantigen Hydrogel Vaccine Combined with PD-1 and CTLA-4 Double Blockade Elicits Antitumor Response in Liver Metastases by Activating Intratumoral CD8(+)CD69(+) T Cells,” Journal for Immunotherapy of Cancer 12, no. 12 (2024).

[285] Q. Gou, B. Yan, Y. Duan, et al., “Ubiquitination of CD47 Regulates Innate Anti-Tumor Immune Response,” Advanced Science (2024): e2412205.

[286] J. Wei, W. Li, P. Zhang, F. Guo, and M. Liu, “Current Trends in Sensitizing Immune Checkpoint Inhibitors for Cancer Treatment,” Molecular Cancer 23, no. 1 (2024): 279.

[287] Y. Xie, Y. Liu, M. Lin, et al., “Targeting ATM Enhances Radiation Sensitivity of Colorectal Cancer by Potentiating Radiation-induced Cell Death and Antitumor Immunity,” Journal of Advanced Research (2024).

[288] Y. Zhan, F. Tian, W. Fan, et al., “Targeting piRNA-137463 Inhibits Tumor Progression and Boosts Sensitivity to Immune Checkpoint Blockade via De Novo Cholesterol Biosynthesis in Lung Adenocarcinoma,” Advanced Science (2024): e2414100.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.